Bioptigen ophthalmic SD-OCT system earns CE Mark

Medical device developer Bioptigen has received regulatory approval to market its handheld Envisu C2000-series ophthalmic spectral-domain optical coherence tomography (SD-OCT) systems for clinical use within the EU.

Medical device developer Bioptigen (Research Triangle Park, NC) has received regulatory approval to market its handheld Envisu C2000-series ophthalmic spectral-domain optical coherence tomography (SD-OCT) systems for clinical use within the EU. The systems use low-power, near-infrared (IR) light to generate real-time, high-resolution, depth-resolved images of eye structures, enabling further understanding in disease progression, detection, and treatment.

The Envisu C2000-series should prove especially useful for physicians treating non-ambulatory patients, as well as those suffering from conditions such as nystagmus, which causes involuntary eye movement, says Dr. Eric Buckland, Bioptigen's president and CEO.

Availability of Envisu C-series handheld clinical ophthalmic imaging systems in the U.S. is dependent upon review and market clearance by the U.S. FDA.

The National Institutes of Health recently awarded Bioptigen a grant to investigate a compact, handheld device for use with premature and neonatal infants.

For more information, please visit www.bioptigen.com.

-----

Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Follow OptoIQ on your iPhone; download the free app here.

Subscribe now to BioOptics World magazine; it's free!

More in Biophotonics Tools